nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—Mental disability—Doxorubicin—liver cancer	0.00181	0.00181	CcSEcCtD
Temozolomide—Gastrointestinal pain—Sorafenib—liver cancer	0.00178	0.00178	CcSEcCtD
Temozolomide—Hot flush—Epirubicin—liver cancer	0.00175	0.00175	CcSEcCtD
Temozolomide—Thrombophlebitis—Doxorubicin—liver cancer	0.00175	0.00175	CcSEcCtD
Temozolomide—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00174	0.00174	CcSEcCtD
Temozolomide—Dermatitis exfoliative—Epirubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Temozolomide—Menopausal symptoms—Epirubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Temozolomide—Urticaria—Sorafenib—liver cancer	0.00173	0.00173	CcSEcCtD
Temozolomide—Abdominal pain—Sorafenib—liver cancer	0.00172	0.00172	CcSEcCtD
Temozolomide—Body temperature increased—Sorafenib—liver cancer	0.00172	0.00172	CcSEcCtD
Temozolomide—Purpura—Epirubicin—liver cancer	0.0017	0.0017	CcSEcCtD
Temozolomide—Vascular purpura—Doxorubicin—liver cancer	0.00169	0.00169	CcSEcCtD
Temozolomide—Hepatic failure—Doxorubicin—liver cancer	0.00168	0.00168	CcSEcCtD
Temozolomide—Eye pain—Doxorubicin—liver cancer	0.00168	0.00168	CcSEcCtD
Temozolomide—Diplopia—Epirubicin—liver cancer	0.00163	0.00163	CcSEcCtD
Temozolomide—Hot flush—Doxorubicin—liver cancer	0.00162	0.00162	CcSEcCtD
Temozolomide—Affect lability—Epirubicin—liver cancer	0.00161	0.00161	CcSEcCtD
Temozolomide—Dermatitis exfoliative—Doxorubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Temozolomide—Menopausal symptoms—Doxorubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Temozolomide—Hypersensitivity—Sorafenib—liver cancer	0.0016	0.0016	CcSEcCtD
Temozolomide—Face oedema—Epirubicin—liver cancer	0.00158	0.00158	CcSEcCtD
Temozolomide—Purpura—Doxorubicin—liver cancer	0.00157	0.00157	CcSEcCtD
Temozolomide—Asthenia—Sorafenib—liver cancer	0.00156	0.00156	CcSEcCtD
Temozolomide—Mood swings—Epirubicin—liver cancer	0.00155	0.00155	CcSEcCtD
Temozolomide—Pruritus—Sorafenib—liver cancer	0.00154	0.00154	CcSEcCtD
Temozolomide—Ataxia—Epirubicin—liver cancer	0.00154	0.00154	CcSEcCtD
Temozolomide—Dehydration—Epirubicin—liver cancer	0.00152	0.00152	CcSEcCtD
Temozolomide—Diplopia—Doxorubicin—liver cancer	0.00151	0.00151	CcSEcCtD
Temozolomide—Dry skin—Epirubicin—liver cancer	0.0015	0.0015	CcSEcCtD
Temozolomide—Affect lability—Doxorubicin—liver cancer	0.00149	0.00149	CcSEcCtD
Temozolomide—Hypokalaemia—Epirubicin—liver cancer	0.00149	0.00149	CcSEcCtD
Temozolomide—Diarrhoea—Sorafenib—liver cancer	0.00149	0.00149	CcSEcCtD
Temozolomide—Breast disorder—Epirubicin—liver cancer	0.00148	0.00148	CcSEcCtD
Temozolomide—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00147	0.00147	CcSEcCtD
Temozolomide—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00147	0.00147	CcSEcCtD
Temozolomide—Face oedema—Doxorubicin—liver cancer	0.00146	0.00146	CcSEcCtD
Temozolomide—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00144	0.00144	CcSEcCtD
Temozolomide—Muscular weakness—Epirubicin—liver cancer	0.00144	0.00144	CcSEcCtD
Temozolomide—Dizziness—Sorafenib—liver cancer	0.00144	0.00144	CcSEcCtD
Temozolomide—Mood swings—Doxorubicin—liver cancer	0.00143	0.00143	CcSEcCtD
Temozolomide—Abdominal distension—Epirubicin—liver cancer	0.00142	0.00142	CcSEcCtD
Temozolomide—Ataxia—Doxorubicin—liver cancer	0.00142	0.00142	CcSEcCtD
Temozolomide—Dysphagia—Epirubicin—liver cancer	0.00141	0.00141	CcSEcCtD
Temozolomide—Dehydration—Doxorubicin—liver cancer	0.00141	0.00141	CcSEcCtD
Temozolomide—Dry skin—Doxorubicin—liver cancer	0.00139	0.00139	CcSEcCtD
Temozolomide—Vomiting—Sorafenib—liver cancer	0.00138	0.00138	CcSEcCtD
Temozolomide—Hypokalaemia—Doxorubicin—liver cancer	0.00138	0.00138	CcSEcCtD
Temozolomide—Rash—Sorafenib—liver cancer	0.00137	0.00137	CcSEcCtD
Temozolomide—Dermatitis—Sorafenib—liver cancer	0.00137	0.00137	CcSEcCtD
Temozolomide—Breast disorder—Doxorubicin—liver cancer	0.00137	0.00137	CcSEcCtD
Temozolomide—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00136	0.00136	CcSEcCtD
Temozolomide—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00136	0.00136	CcSEcCtD
Temozolomide—Headache—Sorafenib—liver cancer	0.00136	0.00136	CcSEcCtD
Temozolomide—Bronchitis—Epirubicin—liver cancer	0.00136	0.00136	CcSEcCtD
Temozolomide—Pancytopenia—Epirubicin—liver cancer	0.00134	0.00134	CcSEcCtD
Temozolomide—Muscular weakness—Doxorubicin—liver cancer	0.00133	0.00133	CcSEcCtD
Temozolomide—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00133	0.00133	CcSEcCtD
Temozolomide—Neutropenia—Epirubicin—liver cancer	0.00132	0.00132	CcSEcCtD
Temozolomide—Dysuria—Epirubicin—liver cancer	0.00132	0.00132	CcSEcCtD
Temozolomide—Abdominal distension—Doxorubicin—liver cancer	0.00132	0.00132	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Epirubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Temozolomide—Dysphagia—Doxorubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Temozolomide—Pollakiuria—Epirubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Temozolomide—Nausea—Sorafenib—liver cancer	0.00129	0.00129	CcSEcCtD
Temozolomide—Photosensitivity reaction—Epirubicin—liver cancer	0.00129	0.00129	CcSEcCtD
Temozolomide—Weight increased—Epirubicin—liver cancer	0.00129	0.00129	CcSEcCtD
Temozolomide—Weight decreased—Epirubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Temozolomide—Hyperglycaemia—Epirubicin—liver cancer	0.00127	0.00127	CcSEcCtD
Temozolomide—Pneumonia—Epirubicin—liver cancer	0.00127	0.00127	CcSEcCtD
Temozolomide—Infestation NOS—Epirubicin—liver cancer	0.00126	0.00126	CcSEcCtD
Temozolomide—Infestation—Epirubicin—liver cancer	0.00126	0.00126	CcSEcCtD
Temozolomide—Bronchitis—Doxorubicin—liver cancer	0.00126	0.00126	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Temozolomide—Pancytopenia—Doxorubicin—liver cancer	0.00124	0.00124	CcSEcCtD
Temozolomide—Neuropathy peripheral—Epirubicin—liver cancer	0.00123	0.00123	CcSEcCtD
Temozolomide—Stomatitis—Epirubicin—liver cancer	0.00123	0.00123	CcSEcCtD
Temozolomide—Urinary tract infection—Epirubicin—liver cancer	0.00122	0.00122	CcSEcCtD
Temozolomide—Dysuria—Doxorubicin—liver cancer	0.00122	0.00122	CcSEcCtD
Temozolomide—Neutropenia—Doxorubicin—liver cancer	0.00122	0.00122	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00121	0.00121	CcSEcCtD
Temozolomide—Pollakiuria—Doxorubicin—liver cancer	0.00121	0.00121	CcSEcCtD
Temozolomide—Photosensitivity reaction—Doxorubicin—liver cancer	0.00119	0.00119	CcSEcCtD
Temozolomide—Hepatobiliary disease—Epirubicin—liver cancer	0.00119	0.00119	CcSEcCtD
Temozolomide—Weight increased—Doxorubicin—liver cancer	0.00119	0.00119	CcSEcCtD
Temozolomide—Weight decreased—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Temozolomide—Sinusitis—Epirubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Temozolomide—Hyperglycaemia—Doxorubicin—liver cancer	0.00118	0.00118	CcSEcCtD
Temozolomide—Pneumonia—Doxorubicin—liver cancer	0.00117	0.00117	CcSEcCtD
Temozolomide—Infestation—Doxorubicin—liver cancer	0.00117	0.00117	CcSEcCtD
Temozolomide—Infestation NOS—Doxorubicin—liver cancer	0.00117	0.00117	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00116	0.00116	CcSEcCtD
Temozolomide—Neuropathy peripheral—Doxorubicin—liver cancer	0.00114	0.00114	CcSEcCtD
Temozolomide—Haemoglobin—Epirubicin—liver cancer	0.00114	0.00114	CcSEcCtD
Temozolomide—Stomatitis—Doxorubicin—liver cancer	0.00114	0.00114	CcSEcCtD
Temozolomide—Urinary tract infection—Doxorubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Temozolomide—Haemorrhage—Epirubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Temozolomide—Hepatitis—Epirubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Temozolomide—Hypoaesthesia—Epirubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Temozolomide—Pharyngitis—Epirubicin—liver cancer	0.00112	0.00112	CcSEcCtD
Temozolomide—Urinary tract disorder—Epirubicin—liver cancer	0.00112	0.00112	CcSEcCtD
Temozolomide—Oedema peripheral—Epirubicin—liver cancer	0.00111	0.00111	CcSEcCtD
Temozolomide—Connective tissue disorder—Epirubicin—liver cancer	0.00111	0.00111	CcSEcCtD
Temozolomide—Urethral disorder—Epirubicin—liver cancer	0.00111	0.00111	CcSEcCtD
Temozolomide—Hepatobiliary disease—Doxorubicin—liver cancer	0.0011	0.0011	CcSEcCtD
Temozolomide—Sinusitis—Doxorubicin—liver cancer	0.00109	0.00109	CcSEcCtD
Temozolomide—Visual impairment—Epirubicin—liver cancer	0.00109	0.00109	CcSEcCtD
Temozolomide—Erythema multiforme—Epirubicin—liver cancer	0.00107	0.00107	CcSEcCtD
Temozolomide—Eye disorder—Epirubicin—liver cancer	0.00106	0.00106	CcSEcCtD
Temozolomide—Tinnitus—Epirubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Temozolomide—Haemoglobin—Doxorubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Temozolomide—Flushing—Epirubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Temozolomide—Cardiac disorder—Epirubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Temozolomide—Haemorrhage—Doxorubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Temozolomide—Hepatitis—Doxorubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Temozolomide—Hypoaesthesia—Doxorubicin—liver cancer	0.00104	0.00104	CcSEcCtD
Temozolomide—Pharyngitis—Doxorubicin—liver cancer	0.00104	0.00104	CcSEcCtD
Temozolomide—Urinary tract disorder—Doxorubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Temozolomide—Oedema peripheral—Doxorubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Temozolomide—Connective tissue disorder—Doxorubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Temozolomide—Angiopathy—Epirubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Temozolomide—Urethral disorder—Doxorubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Temozolomide—Immune system disorder—Epirubicin—liver cancer	0.00102	0.00102	CcSEcCtD
Temozolomide—Mediastinal disorder—Epirubicin—liver cancer	0.00102	0.00102	CcSEcCtD
Temozolomide—Chills—Epirubicin—liver cancer	0.00101	0.00101	CcSEcCtD
Temozolomide—Visual impairment—Doxorubicin—liver cancer	0.00101	0.00101	CcSEcCtD
Temozolomide—Alopecia—Epirubicin—liver cancer	0.000999	0.000999	CcSEcCtD
Temozolomide—Mental disorder—Epirubicin—liver cancer	0.000991	0.000991	CcSEcCtD
Temozolomide—Erythema multiforme—Doxorubicin—liver cancer	0.000989	0.000989	CcSEcCtD
Temozolomide—Malnutrition—Epirubicin—liver cancer	0.000984	0.000984	CcSEcCtD
Temozolomide—Erythema—Epirubicin—liver cancer	0.000984	0.000984	CcSEcCtD
Temozolomide—Eye disorder—Doxorubicin—liver cancer	0.000978	0.000978	CcSEcCtD
Temozolomide—Tinnitus—Doxorubicin—liver cancer	0.000975	0.000975	CcSEcCtD
Temozolomide—Cardiac disorder—Doxorubicin—liver cancer	0.000971	0.000971	CcSEcCtD
Temozolomide—Flushing—Doxorubicin—liver cancer	0.000971	0.000971	CcSEcCtD
Temozolomide—Dysgeusia—Epirubicin—liver cancer	0.000964	0.000964	CcSEcCtD
Temozolomide—Back pain—Epirubicin—liver cancer	0.000952	0.000952	CcSEcCtD
Temozolomide—Angiopathy—Doxorubicin—liver cancer	0.000949	0.000949	CcSEcCtD
Temozolomide—Immune system disorder—Doxorubicin—liver cancer	0.000945	0.000945	CcSEcCtD
Temozolomide—Mediastinal disorder—Doxorubicin—liver cancer	0.000943	0.000943	CcSEcCtD
Temozolomide—Chills—Doxorubicin—liver cancer	0.000939	0.000939	CcSEcCtD
Temozolomide—Vision blurred—Epirubicin—liver cancer	0.000928	0.000928	CcSEcCtD
Temozolomide—Alopecia—Doxorubicin—liver cancer	0.000925	0.000925	CcSEcCtD
Temozolomide—Mental disorder—Doxorubicin—liver cancer	0.000917	0.000917	CcSEcCtD
Temozolomide—Ill-defined disorder—Epirubicin—liver cancer	0.000913	0.000913	CcSEcCtD
Temozolomide—Malnutrition—Doxorubicin—liver cancer	0.000911	0.000911	CcSEcCtD
Temozolomide—Erythema—Doxorubicin—liver cancer	0.000911	0.000911	CcSEcCtD
Temozolomide—Anaemia—Epirubicin—liver cancer	0.00091	0.00091	CcSEcCtD
Temozolomide—Agitation—Epirubicin—liver cancer	0.000905	0.000905	CcSEcCtD
Temozolomide—Dysgeusia—Doxorubicin—liver cancer	0.000892	0.000892	CcSEcCtD
Temozolomide—Malaise—Epirubicin—liver cancer	0.000888	0.000888	CcSEcCtD
Temozolomide—Vertigo—Epirubicin—liver cancer	0.000884	0.000884	CcSEcCtD
Temozolomide—Leukopenia—Epirubicin—liver cancer	0.000881	0.000881	CcSEcCtD
Temozolomide—Back pain—Doxorubicin—liver cancer	0.000881	0.000881	CcSEcCtD
Temozolomide—Palpitations—Epirubicin—liver cancer	0.00087	0.00087	CcSEcCtD
Temozolomide—Cough—Epirubicin—liver cancer	0.000859	0.000859	CcSEcCtD
Temozolomide—Vision blurred—Doxorubicin—liver cancer	0.000858	0.000858	CcSEcCtD
Temozolomide—Convulsion—Epirubicin—liver cancer	0.000853	0.000853	CcSEcCtD
Temozolomide—Hypertension—Epirubicin—liver cancer	0.00085	0.00085	CcSEcCtD
Temozolomide—Ill-defined disorder—Doxorubicin—liver cancer	0.000845	0.000845	CcSEcCtD
Temozolomide—Anaemia—Doxorubicin—liver cancer	0.000842	0.000842	CcSEcCtD
Temozolomide—Arthralgia—Epirubicin—liver cancer	0.000838	0.000838	CcSEcCtD
Temozolomide—Myalgia—Epirubicin—liver cancer	0.000838	0.000838	CcSEcCtD
Temozolomide—Agitation—Doxorubicin—liver cancer	0.000837	0.000837	CcSEcCtD
Temozolomide—Anxiety—Epirubicin—liver cancer	0.000835	0.000835	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000832	0.000832	CcSEcCtD
Temozolomide—Discomfort—Epirubicin—liver cancer	0.000828	0.000828	CcSEcCtD
Temozolomide—Malaise—Doxorubicin—liver cancer	0.000821	0.000821	CcSEcCtD
Temozolomide—Dry mouth—Epirubicin—liver cancer	0.00082	0.00082	CcSEcCtD
Temozolomide—Vertigo—Doxorubicin—liver cancer	0.000818	0.000818	CcSEcCtD
Temozolomide—Leukopenia—Doxorubicin—liver cancer	0.000815	0.000815	CcSEcCtD
Temozolomide—Confusional state—Epirubicin—liver cancer	0.00081	0.00081	CcSEcCtD
Temozolomide—Palpitations—Doxorubicin—liver cancer	0.000805	0.000805	CcSEcCtD
Temozolomide—Anaphylactic shock—Epirubicin—liver cancer	0.000803	0.000803	CcSEcCtD
Temozolomide—Oedema—Epirubicin—liver cancer	0.000803	0.000803	CcSEcCtD
Temozolomide—Infection—Epirubicin—liver cancer	0.000798	0.000798	CcSEcCtD
Temozolomide—Cough—Doxorubicin—liver cancer	0.000795	0.000795	CcSEcCtD
Temozolomide—Convulsion—Doxorubicin—liver cancer	0.000789	0.000789	CcSEcCtD
Temozolomide—Nervous system disorder—Epirubicin—liver cancer	0.000788	0.000788	CcSEcCtD
Temozolomide—Thrombocytopenia—Epirubicin—liver cancer	0.000787	0.000787	CcSEcCtD
Temozolomide—Hypertension—Doxorubicin—liver cancer	0.000786	0.000786	CcSEcCtD
Temozolomide—Skin disorder—Epirubicin—liver cancer	0.00078	0.00078	CcSEcCtD
Temozolomide—Hyperhidrosis—Epirubicin—liver cancer	0.000777	0.000777	CcSEcCtD
Temozolomide—Myalgia—Doxorubicin—liver cancer	0.000775	0.000775	CcSEcCtD
Temozolomide—Arthralgia—Doxorubicin—liver cancer	0.000775	0.000775	CcSEcCtD
Temozolomide—Anxiety—Doxorubicin—liver cancer	0.000773	0.000773	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00077	0.00077	CcSEcCtD
Temozolomide—Discomfort—Doxorubicin—liver cancer	0.000766	0.000766	CcSEcCtD
Temozolomide—Anorexia—Epirubicin—liver cancer	0.000766	0.000766	CcSEcCtD
Temozolomide—Dry mouth—Doxorubicin—liver cancer	0.000758	0.000758	CcSEcCtD
Temozolomide—Confusional state—Doxorubicin—liver cancer	0.000749	0.000749	CcSEcCtD
Temozolomide—Anaphylactic shock—Doxorubicin—liver cancer	0.000743	0.000743	CcSEcCtD
Temozolomide—Oedema—Doxorubicin—liver cancer	0.000743	0.000743	CcSEcCtD
Temozolomide—Infection—Doxorubicin—liver cancer	0.000738	0.000738	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000732	0.000732	CcSEcCtD
Temozolomide—Nervous system disorder—Doxorubicin—liver cancer	0.000729	0.000729	CcSEcCtD
Temozolomide—Thrombocytopenia—Doxorubicin—liver cancer	0.000728	0.000728	CcSEcCtD
Temozolomide—Insomnia—Epirubicin—liver cancer	0.000727	0.000727	CcSEcCtD
Temozolomide—Skin disorder—Doxorubicin—liver cancer	0.000722	0.000722	CcSEcCtD
Temozolomide—Paraesthesia—Epirubicin—liver cancer	0.000721	0.000721	CcSEcCtD
Temozolomide—Hyperhidrosis—Doxorubicin—liver cancer	0.000719	0.000719	CcSEcCtD
Temozolomide—Dyspnoea—Epirubicin—liver cancer	0.000716	0.000716	CcSEcCtD
Temozolomide—Somnolence—Epirubicin—liver cancer	0.000714	0.000714	CcSEcCtD
Temozolomide—Anorexia—Doxorubicin—liver cancer	0.000709	0.000709	CcSEcCtD
Temozolomide—Dyspepsia—Epirubicin—liver cancer	0.000707	0.000707	CcSEcCtD
Temozolomide—Decreased appetite—Epirubicin—liver cancer	0.000698	0.000698	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Epirubicin—liver cancer	0.000694	0.000694	CcSEcCtD
Temozolomide—Fatigue—Epirubicin—liver cancer	0.000693	0.000693	CcSEcCtD
Temozolomide—Pain—Epirubicin—liver cancer	0.000687	0.000687	CcSEcCtD
Temozolomide—Constipation—Epirubicin—liver cancer	0.000687	0.000687	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000677	0.000677	CcSEcCtD
Temozolomide—Insomnia—Doxorubicin—liver cancer	0.000672	0.000672	CcSEcCtD
Temozolomide—Paraesthesia—Doxorubicin—liver cancer	0.000667	0.000667	CcSEcCtD
Temozolomide—Dyspnoea—Doxorubicin—liver cancer	0.000663	0.000663	CcSEcCtD
Temozolomide—Feeling abnormal—Epirubicin—liver cancer	0.000662	0.000662	CcSEcCtD
Temozolomide—Somnolence—Doxorubicin—liver cancer	0.000661	0.000661	CcSEcCtD
Temozolomide—Gastrointestinal pain—Epirubicin—liver cancer	0.000657	0.000657	CcSEcCtD
Temozolomide—Dyspepsia—Doxorubicin—liver cancer	0.000654	0.000654	CcSEcCtD
Temozolomide—Decreased appetite—Doxorubicin—liver cancer	0.000646	0.000646	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000642	0.000642	CcSEcCtD
Temozolomide—Fatigue—Doxorubicin—liver cancer	0.000641	0.000641	CcSEcCtD
Temozolomide—Urticaria—Epirubicin—liver cancer	0.000638	0.000638	CcSEcCtD
Temozolomide—Pain—Doxorubicin—liver cancer	0.000636	0.000636	CcSEcCtD
Temozolomide—Constipation—Doxorubicin—liver cancer	0.000636	0.000636	CcSEcCtD
Temozolomide—Abdominal pain—Epirubicin—liver cancer	0.000635	0.000635	CcSEcCtD
Temozolomide—Body temperature increased—Epirubicin—liver cancer	0.000635	0.000635	CcSEcCtD
Temozolomide—Feeling abnormal—Doxorubicin—liver cancer	0.000613	0.000613	CcSEcCtD
Temozolomide—Gastrointestinal pain—Doxorubicin—liver cancer	0.000608	0.000608	CcSEcCtD
Temozolomide—Hypersensitivity—Epirubicin—liver cancer	0.000592	0.000592	CcSEcCtD
Temozolomide—Urticaria—Doxorubicin—liver cancer	0.000591	0.000591	CcSEcCtD
Temozolomide—Body temperature increased—Doxorubicin—liver cancer	0.000588	0.000588	CcSEcCtD
Temozolomide—Abdominal pain—Doxorubicin—liver cancer	0.000588	0.000588	CcSEcCtD
Temozolomide—Asthenia—Epirubicin—liver cancer	0.000576	0.000576	CcSEcCtD
Temozolomide—Pruritus—Epirubicin—liver cancer	0.000568	0.000568	CcSEcCtD
Temozolomide—Diarrhoea—Epirubicin—liver cancer	0.00055	0.00055	CcSEcCtD
Temozolomide—Hypersensitivity—Doxorubicin—liver cancer	0.000548	0.000548	CcSEcCtD
Temozolomide—Asthenia—Doxorubicin—liver cancer	0.000533	0.000533	CcSEcCtD
Temozolomide—Dizziness—Epirubicin—liver cancer	0.000531	0.000531	CcSEcCtD
Temozolomide—Pruritus—Doxorubicin—liver cancer	0.000526	0.000526	CcSEcCtD
Temozolomide—Vomiting—Epirubicin—liver cancer	0.000511	0.000511	CcSEcCtD
Temozolomide—Diarrhoea—Doxorubicin—liver cancer	0.000509	0.000509	CcSEcCtD
Temozolomide—Rash—Epirubicin—liver cancer	0.000507	0.000507	CcSEcCtD
Temozolomide—Dermatitis—Epirubicin—liver cancer	0.000506	0.000506	CcSEcCtD
Temozolomide—Headache—Epirubicin—liver cancer	0.000503	0.000503	CcSEcCtD
Temozolomide—Dizziness—Doxorubicin—liver cancer	0.000492	0.000492	CcSEcCtD
Temozolomide—Nausea—Epirubicin—liver cancer	0.000477	0.000477	CcSEcCtD
Temozolomide—Vomiting—Doxorubicin—liver cancer	0.000473	0.000473	CcSEcCtD
Temozolomide—Rash—Doxorubicin—liver cancer	0.000469	0.000469	CcSEcCtD
Temozolomide—Dermatitis—Doxorubicin—liver cancer	0.000468	0.000468	CcSEcCtD
Temozolomide—Headache—Doxorubicin—liver cancer	0.000466	0.000466	CcSEcCtD
Temozolomide—Nausea—Doxorubicin—liver cancer	0.000442	0.000442	CcSEcCtD
